Supernus Pharmaceuticals, Bristol-Myers Squibb, and Merck are identified as operating within the branded pharmaceuticals segment.
2 reports, 1 independent
Updated Aug 3
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Supernus Pharmaceuticals, Bristol-Myers Squibb, and Merck are identified as operating within the branded pharmaceuticals segment.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Supernus Pharmaceuticals (United States)
company in Rockville, United States
Nothing else this week.
-
Bristol-Myers Squibb
American pharmaceutical company
-
Merck
public company in Indonesia
Related events
- Bristol-Myers Squibb and Novo Nordisk are noted as competitors in the healthcare sector.
- A group of major pharmaceutical companies, including AbbVie, Bristol-Myers Squibb, Amgen, Pfizer, Moderna, and Merck, are noted as peers operating in the highly regulated pharmaceutical sector.
- AbbVie, Johnson & Johnson, Bristol-Myers Squibb, and Amgen are innovating targeted, cost-effective therapies for psoriatic arthritis.
- Bristol-Myers Squibb and AbbVie secured regulatory approval for a therapy in the US.
- Major pharmaceutical companies are competing for investment capital.
Coverage
Newest first; wire copies grouped- StockStorySupernus Pharmaceuticals (SUPN) Reports Earnings Tomorrow: What To Expect Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be reporting results this Tuesday afternoon. Her